Multicenter Open-trial of Steroid pulse therapy for SJS/TEN

Multicenter Open-trial of Steroid pulse therapy for SJS/TEN - MOSST Study

Status

Active, not recruiting

Phases

Phase 3

Study type

Interventional

Source

JPRN

Registry ID

JPRN-UMIN000028037

Enrollment

Registered

2017-07-06

Start date

2017-07-06

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

SJS/TEN

Interventions

Initiation of steroid pulse therapy within 3 days from onset

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: 1.Cases with definite diagnosis of SJS/TEN 2.Blister or epidermolysis area with more than 1% of body surface area 3.New formation of blister or erythema 4.Obtaining informed consent 5.Within 3 days from onset

Exclusion criteria

Exclusion criteria: 1.Medication of Immunosuppressive or Immunomodulatory drugs for more than 3 days within 7days from onset or Immunosuppressive such as plasmapheresis 2.History of allergy to preservative products in adrenal cortical steroid 4.Affected severe sepsis 5.Affected severe cardiac disease 6.Active gastric ulceror bleeding 7.Uncontrolled DM 8.History of leg gangrene 9.active virus disease 10.Hepatitis B virus carrier 11.Untreated tuberculosis 12.Hemodialysis 13.Complicating drug-induced hypersensitivity syndrome 14.Decision by primary doctor

Design outcomes

Primary

Measure	Time frame
Scoring clinical evaluations; skin involvement, lip/oral mucosa involvement, eye involvement, general findings	—

Secondary

Measure	Time frame
Vital sign	—

Countries

Japan,Asia(except Japan),Europe

Contacts

Public ContactHiroyuki Niihara

Faculty of Medicine SHIMANE University Dermatology

ofcourse@med.shimane-u.ac.jp0853-20-2210

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026